Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATIN platform trial of concurrent tyrosine kinase inhibitor use with cranial radiotherapy in NSCLC brain metastases
NL-OMON54721Phase 4Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2018
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Maastricht University Medical Center+. Primary endpoints: Acute severe toxicity at 2 weeks after cranial radiotherapy and Neurotoxicity at 4 months. Started Jul 2018; status: terminated.
02
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NL-OMON54721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54721.